Norovirus is acknowledged to be a leading cause of acute gastroenteritis worldwide, and its importance as a cause of chronic infection in immune deficient hosts is increasingly recognised.
Notwithstanding these limitations, we present here the current understanding of the immune response to norovirus and how primary immune deficiency might subvert host defences to predispose to chronic infection. We summarise clinical reports of norovirus infection in primary immunodeficiency conditions and discuss potential options for therapy in this challenging population. At the current time, no vaccine or antiviral therapy has been licensed. 17 
| THE IMMUNE RESPONSE TO NOROVIRUS AND ITS COMPROMISE IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCY
The immunological response to norovirus infection remains incompletely understood (as recently reviewed 18 ), with progress thwarted by the lack of available in vitro models. Indeed, even the types of host cell infected by norovirus are not well established-although varying evidence exists for tropism towards mucosal epithelial cells, B cells, and antigen-presenting cells. 18, 19 Nevertheless, it is clear from human studies that there is rapid and broad immune activation in response to infection in immunocompetent hosts, both systemically 20 and in stool, 21 with subsequent development of antibody responses. Newman et al document a rise in Th1 (eg, IFNγ), proinflammatory (eg, IL-1β, IL-6, and IL-8) and Th2 (eg, IL-4 and IL-10) cytokines in serum, 20 while
Ko et al predominantly observed increased IL-2 and IFNγ in faeces. 21 In relation to chronic infection in patients with primary immunode- Evidence from animal models suggests an important role for antibodies in clearance of infection, 12, 22 and their appearance may correlate with virological control. Chachu et al found in a murine model that functional B cells or specific norovirus antibodies could affect viral clearance in RAG-/-combined (B and T cell) immunodeficient mice. 23 However, severe combined immunodeficiency (SCID) children with B-cell deficiency had tenfold lower levels of norovirus than SCID children in whom B cells were intact (perhaps explained by B cells acting as a site for viral replication), underlining the complexity of immune responses.
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Virus-specific CD8+ cytotoxic T cells also contribute significantly to viral clearance in mice, 25, 26 with perhaps a particular role for perforin. 26 Tomov et al observed that murine norovirus strains achieving chronic infection elicited a poorer CD8+ T cell response in terms of cytokine and granzyme production and that adoptive transfer of this cell type to RAG -/-mice reduced viral shedding.
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CD4+ T cells also appear important for viral clearance 26 and protective immunity against further infection. 27 These lymphocytes activate antigen presenting cells, facilitate B cell development including antibody class-switching, and stimulate cytotoxic T cells. As mentioned above, both Th1 and Th2 cytokines are observed in the robust immune response of normal hosts, 20, 21 although mouse models suggest that interferon-gamma may be redundant for virological clearance.
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Type I interferons limit viral replication in vitro 28 and speed clearance in vivo, 29 while IFN-α/βR-/-mice suffer far higher viral loads than wild-type controls. 30 Recent evidence has also strongly implicated Type III interferons in mice, 31, 32 with effective cure of chronically infected animals achieved via administration of IFN-λ.
In totem, the available data suggest that a coordinated response of innate mechanisms (interferons), CD8+ cytotoxicity, and a humoral response, presumably with CD4+ orchestration, is associated with norovirus clearance. There may be redundancy within these mechanisms, and, although antibody-deficiency is common in patients with chronic infection, it seems likely that an additional component of The mechanism by which cytotoxic T cells may become activated in patients with chronic norovirus infection is unclear, given that compromise of the CD4+ T cell compartment is common in these individuals. 8, 18 Although direct antigen presentation from infected cells may be important, a highly implicated mediator in coeliac disease is the cytokine IL-15, 33 which activates and upregulates the cytotoxicity of IELs as well as impairing response to regulatory T cells. 37 Importantly, this cytokine is secreted from, and expressed on the surface of, dendritic cells and intestinal epithelial cells, 37 and this process may thus be preserved even with severe compromise of CD4 and B cell function.
Such a mechanism remains speculative at present and requires further investigation. 
| PRESENTATION AND COMPLICATIONS OF NOROVIRUS INFECTION IN PRIMARY IMMUNE DEFICIENCY
Primary immune deficiencies are a large, diverse group of disorders classified into major groups of combined immunodeficiencies, combined immunodeficiencies with associated or syndromic features, antibody deficiencies, immune dysregulation, phagocytic defects, defects in innate immunity, autoinflammatory disorders, and complement deficiencies. 38 The commonest symptomatic primary immune deficiency in adults is common variable immune deficiency (CVID). This condition is characterised by a failure in B cell differentiation with defective immunoglobulin production, and coexisting T cell defects are also common. 39 Patients with CVID have a heterogeneous clinical presentation but tend to be susceptible to recurrent infections of the upper and lower respiratory tract, gastrointestinal infections, and experience higher frequencies of inflammatory and autoimmune conditions including inflammatory bowel disease. 40 Norovirus infection in hosts with secondary immunocompromise has been described, 8, 9 and norovirus is recognised to be a frequent enteric pathogen in these patient groups. Norovirus infection in hosts with immune deficiencies is often characterised by a chronic rather than acute course, severe diarrhoea, prolonged viral shedding, and may be complicated by malabsorption, weight loss, organ failure, requirement for parenteral nutrition, and even death. 8 This has been 
and CD4+ T cell cytokine release and proliferation. This results in failure to clear norovirus and a persistent, unchecked CD8+ cytotoxic T cell response causing epithelial damage described in patients after solid organ [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and haematopoietic stem cell transplants (HSCT), 46, 53, [55] [56] [57] [58] [59] patients with malignancy and those receiving chemotherapy, [58] [59] [60] [61] [62] patients with chronic lymphocytic leukaemia, 63 preterm infants, 64 and in an HIV-positive patient. 65 However, in these secondary immunocompromised states, immunosuppression can often be decreased in response to debilitating infection, or immune reconstitution may be expected to occur, aiding the host response to achieve viral clearance. In contrast, patients with primary immune deficiencies have a stable level of immunodeficiency, which may not be easily amenable to correction, and therefore, may have a protracted clinical course and inability to clear infection. 66 Six out of 11 norovirus-infected children had symptoms of diarrhoea, which was complicated by dehydration in 4 cases and malnutrition in 2. The longest duration of diarrhoea reported was 10 months and in the 7 patients followed up with faecal samples, substantial viral excretion was still detected in 4 after a median of 9.5 months follow up. Two patients with norovirus infection had a detectable norovirus viraemia and one of these also had norovirus detectable in the cerebro-spinal fluid. Upper gastrointestinal endoscopy was performed in 3 children: 2 children demonstrated duodenal villous atrophy with moderately higher than normal intraepithelial CD3+ CD8+ lymphocyte counts, one of these cases had slightly higher than normal numbers of apoptotic epithelial cells, with mild polynuclear neutrophil infiltration.
In a retrospective series of 8 adult patients with CVID and a diagnosis of CVID enteropathy, all were found to be positive for norovirus in stool.
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These patients were all symptomatic with varying severity of diarrhoea, nausea, and weight loss, and 5 were dependent on parenteral nutrition.
One patient appeared to have at least 8 years of chronic infection, with detectable norovirus RNA in archived biopsy specimens over this time A retrospective audit of patients attending an adult immunology clinic identified 3 patients with CVID and persistent norovirus infection (defined as 2 or more positive detections of the same virus more than 8 weeks apart). 67 All 3 patients were symptomatic with diarrhoea; 2 patients had severe weight loss (10 and 8 kg); and 1 patient had acute on chronic renal failure, malnutrition, and required long-term parenteral nutrition.
One case report describes a patient with CVID who developed a severe protein-losing enteropathy characterised by diarrhoea, nausea, abdominal pain, significant weight loss, and requirement for parenteral nutrition and was found to have a chronic enteral infection with both human parechovirus type 1 and norovirus for at least 2 years. 68 Biopsies from the oesophagus, antrum, duodenum, distal ileum, colon, and sigmoid all showed lymphocytic infiltration with a marked increase of T cells. The duodenum showed villous atrophy, and there was also apoptotic colitis.
Prolonged symptoms of norovirus gastroenteritis have been described in a child with cartilage hair hypoplasia (a rare genetic disorder with autosomal recessive chondrodysplasia and a primary T cell immunodeficiency) who excreted norovirus in the stool for 4 months before HSCT, then again for 5 months following HSCT. 69 The child suffered from diarrhoea, vomiting, weight loss, and occasional fever but made a full recovery after immune reconstitution. In this case, HSCT may have enabled viral clearance due to lymphocyte engraftment. In contrast,
HSCT has been attributed as a cause of norovirus persistence in some primary immune deficiency patients. Xerry et al described 2 infants with primary immune deficiency (1 with Wiskott-Aldrich syndrome and 1 with SCID syndrome) who underwent HSCT from matched unrelated donors then developed norovirus gastroenteritis post-transplant, on day 11 and 34, respectively. 70 The infants excreted norovirus for 69
and 48 days and both were found to be excreting 3 unique strains.
| CHRONIC NOROVIRUS INFECTION AND CVID ENTEROPATHY
A proportion of patients with CVID suffers from a severe chronic enteropathy characterised by diarrhoea and malabsorption. 71, 72 Although the term CVID enteropathy has been used to describe a range of histopathological abnormalities, it is best reserved for those cases with increased IELs, epithelial cell apoptosis, and villous atrophy in the small bowel, 73, 74 although no significant change was seen in histopathological appearance of small bowel biopsies after treatment. 75 These findings may support a role for aberrant, cytotoxic immune responses to chronic norovirus infection, and perhaps other enteric infections, in the aetiology of CVID enteropathy.
| TREATMENT OF CHRONIC NOROVIRUS INFECTION IN IMMUNOCOMPROMISED HOSTS
In immunocompetent patients, the mainstay of therapy for norovirus gastroenteritis remains supportive care during the self-limiting illness. Boosting IL-2 activity in immune deficient hosts could be a target for treatment of norovirus infection, because increased stool IL-2 levels have been measured in norovirus infection. 21 However, IL-2 therapy was unsuccessful in one patient with HIV infection and symptomatic chronic norovirus infection. 65 Two antiviral therapies have been evaluated for efficacy in norovirus infection in immune deficient hosts. Nitazoxanide is a broad-spectrum antimicrobial agent licenced for the treatment of diarrhoea caused by Cryptosporidium spp. and Giardia lamblia, with antiviral effects, thought to work through potentiation of host antiviral activity.
It has been shown to inhibit the replication of norovirus in cell lines 80 and reduce the duration of symptoms in human infection. 81 Activity against norovirus infection has been mixed: one immunosuppressed patient with relapsed refractory acute myeloid leukaemia and chronic graft-versus-host disease after HSCT achieved complete clinical resolution within 4 days of starting a course of oral nitazoxanide, although had ongoing asymptomatic viral shedding for over 30 days. 82 Morris &
Morris similarly described a fast clinical response within 2 to 4 days of starting oral nitazoxanide in 13 out of 13 immunosuppressed or chemotherapy-receiving patients (3 pre-HSCT and 10 after HSCT), with improvements in diarrhoea, nausea, and abdominal pain, 59 although the duration of norovirus infection prior to treatment is not stated. There was variable clearance of stool virus, however. Conversely, a transplant recipient 50 and a patient with CVID, 67 both with prolonged norovirus gastroenteritis, did not respond to treatment with nitazoxanide.
Ribavirin is a broad-spectrum nucleoside analogue antiviral licenced for treatment of HCV and RSV infections, with in vitro activity FIGURE 2 Histological appearances of mucosa in chronic norovirus infection. Formalin-fixed, paraffin-embedded duodenal biopsy tissue was cut to 3-micron thickness and stained with haemotoxylin and eosin. Panels represent 100× magnification images of A, healthy individual with normal villous architecture, B, common variable immunodeficiency patient with chronic norovirus infection, demonstrating villous atrophy and intraepithelial lymphocytosis, and C, coeliac disease patient demonstrating similar appearances to B 
Interleukin-2
Increased stool IL-2 levels measured in norovirus infection 21 Wingfield et al 65 1 patient with HIV infection and symptomatic norovirus infection for 15 months. IL-2 therapy unsuccessful.
Nitazoxanide Broad-spectrum antimicrobial agent with anti-viral effects. Thought to potentiate host anti-viral activity. Shown to inhibit replication of norovirus in cell lines 80 and reduce duration of symptoms in human infection 81 Siddiq et al 82 1 patient with relapsed refractory AML with chronic GVHD after HSCT. On treatment with ponatinib (oral BCR-ABL tyrosine kinase inhibitor) and immunosuppressive therapy. Given oral nitazoxanide 500 mg twice daily for 7 days. Complete clinical resolution within 4 days but ongoing asymptomatic shedding for >30 days. Echenique et al 50 1 patient on immunosuppressive therapy after pancreas transplant. Given oral nitazoxanide (500 mg daily for 5 days). No effect on symptoms or viral excretion. 59 13 patients on immunosuppressive therapy or chemotherapy (3 pre-HSCT, 10 after HSCT). Given oral nitazoxanide (dose dependent on age). All had clinical (Continues) otics. 15 However, a retrospective study of renal transplant recipients, which identified 15 patients with norovirus infection and 1 with sapovirus infection, found empirical antimicrobial therapy to be unsuccessful in 4 out of 4 patients, 42 and a prolonged course of antibiotic treatment for methicillin-resistant Staphylococcus aureus chest infection and Clostridium difficile in a CVID patient with persistent norovirus, had no effect on viral excretion. 67 Furthermore, there are several potential candidates for treatment of chronic norovirus infection, which have not yet been evaluated in immune deficient patients. 17, 88 A promising drug is the nucleoside analogue favipiravir, a broad-spectrum antiviral agent, which may have multiple mechanisms of action. 89 In vitro, it has modest potency again murine norovirus in a cell culture model, 90 and treatment of murine norovirus-infected mice caused more rapid clearance rates of infectious virus via induction of lethal mutagenesis, with higher mutagenic activity and greater efficiency in controlling viral titres than was seen for ribavirin. 91 Because of its current status in development for use in influenza, favipiravir has been administered to greater than 1400 human subjects in clinical trials, with proven safety and tolerability, 92 however, is not yet available for clinical use in norovirus infections.
Morris & Morris
Another nucleoside analogue with possible future use in human norovirus infection is 2′-C-methylcytidine (2CMC) and its derivatives.
2′-C-methylcytidine has been shown to have antimurine norovirus activity in cell culture 93 and to be a potent inhibitor of human norovirus replication in a replicon cell culture model 94, 95 and in a B cell culture system. 96 In mouse models, 2CMC inhibited murine norovirus replication and protected against diarrhoea and mortality, 95 107 Therapies based on these approaches remain in the early stages of development. Abbreviations: AML,acute myeloid leukaemia; CVID, common variable immune deficiency; GVHD,graft versus host disease; HBGA, histo-blood group antigen; HPeV, Human parechoviruses; HSCT, haematopoietic stem cell transplant; INF-α, interferon alpha; IVIG, intravenous immunoglobulin; mTOR, mammalian target of rapamycin. 
| CONCLUSION AND FUTURE DIRECTIONS

